Quest Diagnostics Management
Management criteria checks 4/4
Quest Diagnostics' CEO is Jim Davis, appointed in Nov 2022, has a tenure of 3.17 years. total yearly compensation is $14.40M, comprised of 8.7% salary and 91.3% bonuses, including company stock and options. directly owns 0.11% of the company’s shares, worth $20.90M. The average tenure of the management team and the board of directors is 3.5 years and 6.4 years respectively.
Key information
Jim Davis
Chief executive officer
US$14.4m
Total compensation
| CEO salary percentage | 8.68% |
| CEO tenure | 3.2yrs |
| CEO ownership | 0.1% |
| Management average tenure | 3.5yrs |
| Board average tenure | 6.4yrs |
Recent management updates
Recent updates
Quest Diagnostics: Strong Q3, Steady (Not Spectacular) Growth Ahead
Oct 22Earnings Not Telling The Story For Quest Diagnostics Incorporated (NYSE:DGX)
Aug 20
Return Trends At Quest Diagnostics (NYSE:DGX) Aren't Appealing
Jun 21Is Quest Diagnostics Incorporated (NYSE:DGX) Trading At A 48% Discount?
May 11Quest Diagnostics (NYSE:DGX) Will Pay A Larger Dividend Than Last Year At $0.80
Apr 03Quest Diagnostics (NYSE:DGX) Will Pay A Larger Dividend Than Last Year At $0.80
Mar 20Is Now The Time To Look At Buying Quest Diagnostics Incorporated (NYSE:DGX)?
Mar 17Quest Diagnostics (NYSE:DGX) Is Increasing Its Dividend To $0.80
Feb 27Quest Diagnostics (NYSE:DGX) Has Some Way To Go To Become A Multi-Bagger
Feb 19Quest Diagnostics Incorporated (NYSE:DGX) Yearly Results: Here's What Analysts Are Forecasting For This Year
Feb 02Quest Diagnostics: Good Growth Prospects, But Little To No Upside Left At Current Valuation
Jan 28Quest Diagnostics Incorporated (NYSE:DGX) Could Be Riskier Than It Looks
Jan 26Quest Diagnostics: Organic Growth Leads To Q3 Earnings Beat
Oct 24Quest Diagnostics: The Better Half Of An Emerging Healthcare Duopoly
Oct 15
Expanding Geographic Footprint And Advancing Diagnostics Fuel Revenue And Margin Growth
Strategic expansions and acquisitions, like LifeLabs in Canada and select U.S. lab assets, aim to grow market share and access, potentially boosting revenues.Quest Diagnostics: Beat Down After Beating Q2 Estimates
Jul 28Quest Diagnostics: On A Quest For Growth
Jul 12Quest Diagnostics: Let's Keep Waiting
May 08CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | US$963m |
| Jun 30 2025 | n/a | n/a | US$945m |
| Mar 31 2025 | n/a | n/a | US$892m |
| Dec 31 2024 | US$14m | US$1m | US$866m |
| Sep 30 2024 | n/a | n/a | US$838m |
| Jun 30 2024 | n/a | n/a | US$836m |
| Mar 31 2024 | n/a | n/a | US$842m |
| Dec 31 2023 | US$13m | US$1m | US$850m |
| Sep 30 2023 | n/a | n/a | US$759m |
| Jun 30 2023 | n/a | n/a | US$790m |
| Mar 31 2023 | n/a | n/a | US$789m |
| Dec 31 2022 | US$12m | US$806k | US$942m |
| Sep 30 2022 | n/a | n/a | US$1b |
| Jun 30 2022 | n/a | n/a | US$1b |
| Mar 31 2022 | n/a | n/a | US$2b |
| Dec 31 2021 | US$4m | US$625k | US$2b |
| Sep 30 2021 | n/a | n/a | US$2b |
| Jun 30 2021 | n/a | n/a | US$2b |
| Mar 31 2021 | n/a | n/a | US$2b |
| Dec 31 2020 | US$4m | US$577k | US$1b |
| Sep 30 2020 | n/a | n/a | US$1b |
| Jun 30 2020 | n/a | n/a | US$749m |
| Mar 31 2020 | n/a | n/a | US$771m |
| Dec 31 2019 | US$3m | US$590k | US$835m |
Compensation vs Market: Jim's total compensation ($USD14.40M) is about average for companies of similar size in the US market ($USD13.44M).
Compensation vs Earnings: Jim's compensation has been consistent with company performance over the past year.
CEO
Jim Davis (62 yo)
Mr. James E. Davis, also known as Jim, serves as Chief Executive Officer and President at Quest Diagnostics Incorporated since November 1, 2022 and serves as its Director since November 2022. He served as...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 3.2yrs | US$14.40m | 0.11% $ 20.9m | |
| Executive VP & CFO | 3.5yrs | US$4.07m | 0.023% $ 4.5m | |
| Senior VP & General Counsel | 26.4yrs | US$2.43m | 0.039% $ 7.6m | |
| Executive Vice President of Regional Businesses | no data | US$3.29m | 0.058% $ 11.3m | |
| Senior Vice President of Clinical Solutions | 3.4yrs | US$2.28m | 0.0093% $ 1.8m | |
| Senior VP | 6.8yrs | no data | 0.032% $ 6.1m | |
| Senior VP and Chief Information & Digital Officer | 1.7yrs | no data | no data | |
| Vice President of Investor Relations | no data | no data | no data | |
| Senior VP & Chief Compliance Officer | 3.3yrs | no data | no data | |
| Senior VP and Chief Marketing & Communications Officer | no data | no data | no data | |
| Senior VP & Chief Human Resources Officer | 7.9yrs | no data | no data | |
| Senior Vice President of Strategy | 9.9yrs | no data | no data |
Experienced Management: DGX's management team is considered experienced (3.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 3.2yrs | US$14.40m | 0.11% $ 20.9m | |
| Independent Director | 12yrs | US$342.72k | 0.024% $ 4.6m | |
| Independent Director | 1.7yrs | US$280.10k | no data | |
| Lead Independent Director | 14.1yrs | US$377.97k | no data | |
| Independent Director | 21.1yrs | US$360.72k | 0.026% $ 5.1m | |
| Independent Director | 6.9yrs | US$344.72k | 0.0038% $ 731.4k | |
| Independent Director | 11.5yrs | US$344.72k | 0.015% $ 3.0m | |
| Independent Director | 5.8yrs | US$327.72k | no data | |
| Independent Director | 4.4yrs | US$327.72k | no data | |
| Independent Director | 2.7yrs | US$324.97k | 0.0026% $ 494.1k |
Experienced Board: DGX's board of directors are considered experienced (6.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/06 03:21 |
| End of Day Share Price | 2026/01/05 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Quest Diagnostics Incorporated is covered by 37 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Eric Coldwell | Baird |
| Luke Sergott | Barclays |